Taro Receives FDA Approval For Topicort® (desoximetasone) Topical Spray, 0.25%

  Taro Receives FDA Approval For Topicort® (desoximetasone) Topical Spray,
  0.25%

Business Wire

HAWTHORNE, N.Y. -- April 12, 2013

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) reported today that
it has received approval from the U.S. Food and Drug Administration (“FDA”)
for its New Drug Application (“NDA”) Topicort^® (desoximetasone) Topical
Spray, 0.25%.

Topicort^® (desoximetasone) Topical Spray, 0.25%  is a corticosteroid
indicated for the treatment of plaque psoriasis in patients 18 years of age or
older.

According to industry sources, the corticosteroid spray market is
approximately $100 million in annual sales in the U.S.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the highest
quality healthcare products. For further information on Taro Pharmaceutical
Industries Ltd., please visit Taro’s website at www.taro.com.

Certain statements in this release are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s Topicort^® (desoximetasone) Topical Spray,
0.25%. Although Taro believes the expectations reflected in such
forward-looking statements to be based on reasonable assumptions, it can give
no assurance that its expectations will be attained. Factors that could cause
actual results to differ include industry and market conditions; slower than
anticipated penetration of new markets; marketplace acceptance of Taro’s
Topicort^® (desoximetasone) Topical Spray, 0.25%; changes in the Company’s
financial position; regulatory actions; and other risks detailed from time to
time in the Company’s SEC reports, including its Annual Reports on Form 20-F.
Forward-looking statements speak only as of the date on which they are made.
The Company undertakes no obligation to update, change or revise any
forward-looking statements, whether as a result of new information, additional
or subsequent developments or otherwise.

Contact:

Taro Pharmaceutical Industries Ltd.
William J. Coote, VP and Treasurer, (914) 345-9001
William.Coote@Taro.com
 
Press spacebar to pause and continue. Press esc to stop.